Suppr超能文献

多囊肝疾病中门静脉高压和腹水的处理。

Management of portal hypertension and ascites in polycystic liver disease.

机构信息

Department of Gastroenterology and Hepatology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.

出版信息

Liver Int. 2019 Nov;39(11):2024-2033. doi: 10.1111/liv.14245. Epub 2019 Sep 20.

Abstract

Patients suffering from polycystic liver disease may develop Hepatic Venous Outflow Obstruction, Portal Vein Obstruction and/or Inferior Caval Vein Syndrome because of cystic mass effect. This can cause portal hypertension, leading to ascites, variceal haemorrhage or splenomegaly. For this review, we evaluate the evidence to provide clinical guidance for physicians faced with this complication. Diagnosis is made with imaging such as ultrasound, computed tomography or magnetic resonance imaging. Therapy includes conventional therapy with diuretics and paracentesis, and medical therapy using somatostatin analogues. Based on disease phenotype various (non-)surgical liver-volume reducing therapies, hepatic or portal venous stenting, transjugular intrahepatic portosystemic shunts and liver transplantation may be considered. Because of complicated anatomy, use of high-risk interventions and lack of empirical evidence, patients should be treated in expert centres.

摘要

患有多囊肝疾病的患者可能会由于囊肿的占位效应而发生肝静脉流出道梗阻、门静脉梗阻和/或下腔静脉综合征。这可能导致门静脉高压,从而导致腹水、静脉曲张出血或脾肿大。在这项综述中,我们评估了证据,为面临这一并发症的医生提供临床指导。诊断通过超声、计算机断层扫描或磁共振成像等影像学方法进行。治疗包括使用利尿剂和腹腔穿刺术的常规治疗,以及使用生长抑素类似物的药物治疗。根据疾病表型,可以考虑各种(非)手术性肝体积减少治疗、肝或门静脉支架置入、经颈静脉肝内门体分流术和肝移植。由于解剖结构复杂、高危介入治疗和缺乏经验证据,患者应在专家中心接受治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3b8/6899472/f77162a0abd5/LIV-39-2024-g001.jpg

相似文献

1
Management of portal hypertension and ascites in polycystic liver disease.
Liver Int. 2019 Nov;39(11):2024-2033. doi: 10.1111/liv.14245. Epub 2019 Sep 20.
2
Role of Transjugular Intrahepatic Portosystemic Shunt in the Management of Portal Hypertension: Review and Update of the Literature.
Clin Liver Dis. 2019 Nov;23(4):737-754. doi: 10.1016/j.cld.2019.07.004. Epub 2019 Aug 31.
3
The use and misuse of transjugular intrahepatic portasystemic shunts.
Curr Gastroenterol Rep. 2000 Feb;2(1):61-71. doi: 10.1007/s11894-000-0053-5.
4
Transjugular intrahepatic portosystemic shunt for alveolar echinococcosis of the liver and Budd-Chiari syndrome.
Clin Res Hepatol Gastroenterol. 2018 Sep;42(4):e61-e62. doi: 10.1016/j.clinre.2017.11.007. Epub 2018 Jun 8.
5
Evolving Indications for Tips.
Tech Vasc Interv Radiol. 2016 Mar;19(1):36-41. doi: 10.1053/j.tvir.2016.01.004. Epub 2016 Jan 29.
6
Percutaneous Direct Intrahepatic Portosystemic Shunt Creation in an Infant.
J Vasc Interv Radiol. 2016 Aug;27(8):1251-3. doi: 10.1016/j.jvir.2016.05.004.
7
Selective distal splenorenal shunts for intractable variceal bleeding in pediatric portal hypertension.
J Pediatr Surg. 1995 Aug;30(8):1115-8. doi: 10.1016/0022-3468(95)90000-4.
8
Transjugular intrahepatic portosystemic shunt: current status.
Gastroenterology. 2003 May;124(6):1700-10. doi: 10.1016/s0016-5085(03)00377-9.
9
Utility of endoscopic ultrasound in patients with portal hypertension.
World J Gastroenterol. 2014 Oct 21;20(39):14230-6. doi: 10.3748/wjg.v20.i39.14230.

引用本文的文献

1
Key Aspects in the Nutritional Management of Polycystic Liver Disease Patients.
Nutrients. 2025 Jul 21;17(14):2380. doi: 10.3390/nu17142380.
2
Autosomal dominant polycystic kidney disease: an overview of recent genetic and clinical advances.
Ren Fail. 2025 Dec;47(1):2492374. doi: 10.1080/0886022X.2025.2492374. Epub 2025 Apr 23.
3
Questionnaire PLD-complaint-specific assessment identifies need for therapy in polycystic liver disease: A multi-centric prospective study.
United European Gastroenterol J. 2023 Sep;11(7):633-641. doi: 10.1002/ueg2.12387. Epub 2023 Jun 5.
4
Fatal acute portal vein thrombosis associated with hepatic cysts in a patient with autosomal dominant polycystic kidney disease.
CEN Case Rep. 2024 Feb;13(1):32-36. doi: 10.1007/s13730-023-00795-6. Epub 2023 May 10.
5
Polycystic Liver Disease: Pathophysiology, Diagnosis and Treatment.
Hepat Med. 2022 Sep 29;14:135-161. doi: 10.2147/HMER.S377530. eCollection 2022.
6
Surgical treatment of hepatic xanthogranuloma arising from a giant hepatic cyst causing gastrointestinal obstruction: a case report.
J Surg Case Rep. 2022 Jul 30;2022(7):rjac252. doi: 10.1093/jscr/rjac252. eCollection 2022 Jul.
7
An emergency hybrid procedure that combines endoscopic treatment with partial splenic embolization for bleeding esophagogastric varices.
Radiol Case Rep. 2022 Mar 19;17(5):1640-1645. doi: 10.1016/j.radcr.2022.02.041. eCollection 2022 May.
9
Polycystic liver: automatic segmentation using deep learning on CT is faster and as accurate compared to manual segmentation.
Eur Radiol. 2022 Jul;32(7):4780-4790. doi: 10.1007/s00330-022-08549-1. Epub 2022 Feb 10.
10
A Rare Cause of Cholestasis Related to Polycystic Liver Disease.
GE Port J Gastroenterol. 2021 Feb 12;28(6):443-445. doi: 10.1159/000514008. eCollection 2021 Nov-Dec.

本文引用的文献

1
The management of polycystic liver disease by tolvaptan.
Clin Mol Hepatol. 2020 Jan;26(1):70-73. doi: 10.3350/cmh.2019.0026. Epub 2019 Jun 13.
2
Venous Stent Placement for Refractory Ascites due to Hepatic Venous Outflow Obstruction in Polycystic Liver Disease.
J Vasc Interv Radiol. 2019 Oct;30(10):1617-1619. doi: 10.1016/j.jvir.2018.09.011. Epub 2019 Apr 17.
3
Effect of tolvaptan on the prognosis of patients with hepatic ascites.
Hepatol Res. 2019 Jul;49(7):765-777. doi: 10.1111/hepr.13337. Epub 2019 Apr 30.
4
Clinical response after laparoscopic fenestration of symptomatic hepatic cysts: a systematic review and meta-analysis.
Surg Endosc. 2019 Mar;33(3):691-704. doi: 10.1007/s00464-018-6490-8. Epub 2018 Oct 17.
5
Con: Tolvaptan for autosomal dominant polycystic kidney disease-do we know all the answers?
Nephrol Dial Transplant. 2019 Jan 1;34(1):35-37. doi: 10.1093/ndt/gfy298.
6
7
Ethanol sclerotherapy or polidocanol sclerotherapy for symptomatic hepatic cysts.
United European Gastroenterol J. 2018 Jul;6(6):919-925. doi: 10.1177/2050640618764940. Epub 2018 Mar 8.
8
Management of refractory cirrhotic ascites: challenges and solutions.
Hepat Med. 2018 Jul 3;10:55-71. doi: 10.2147/HMER.S136578. eCollection 2018.
9
Isolated Polycystic Liver Disease: An Unusual Cause of Recurrent Variceal Bleed.
Case Rep Gastrointest Med. 2018 Jun 4;2018:2902709. doi: 10.1155/2018/2902709. eCollection 2018.
10
EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis.
J Hepatol. 2018 Aug;69(2):406-460. doi: 10.1016/j.jhep.2018.03.024. Epub 2018 Apr 10.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验